Nu Skin Enterprises, Inc. (NUS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Nu Skin Enterprises, Inc. (NUS) stock forecast summary
On Oct. 14, 2026, NUS is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Nu Skin Enterprises, Inc. is a small-cap company with a market capitalization of $244M. It ranks number 5 by market capitalization among the 6 Wholesale-Drugs, Proprietaries & Druggists' Sundries issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for NUS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NUS included.
Follow NUS freeNUS price chart and AI forecast
How NUS ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Nu Skin Enterprises, Inc. (NUS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
Valuation & Market
| Metric | NUS | Rank |
|---|---|---|
| Market Cap | $244M | 5/6 |
| P/B Ratio | 0.45x | – |
| Dividend Yield | 4.78% | – |
| EPS | $-4.53 | – |
| Book Value/Share | $11.15 | – |
| Revenue/Share | $28.25 | – |
| FCF/Share | $0.22 | – |
Profitability & Margins
| Metric | NUS | Rank |
|---|---|---|
| ROE | -40.2% | – |
| ROA | -19.5% | 5/8 |
| ROIC | -1.2% | 5/6 |
| Gross Margin | 69.2% | 2/7 |
| Operating Margin | -0.8% | 5/7 |
| Net Margin | -15.9% | 5/8 |
| EBT Margin | -1.9% | 5/8 |
| Tax Rate | -717.1% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | NUS | Rank |
|---|---|---|
| Current Ratio | 1.98x | 1/7 |
| Quick Ratio | 1.24x | 2/7 |
| D/E Ratio | 1.07x | – |
| Financial Leverage | 2.07x | – |
| Interest Coverage | 1.4x | 4/7 |
| Working Capital | $252M | 1/7 |
Cash Flow
| Metric | NUS | Rank |
|---|---|---|
| Operating Cash Flow | $51M | 5/8 |
| Free Cash Flow | $11M | 4/5 |
| Capital Spending | -$40M | 2/5 |
| OCF Growth YoY | -45.6% | 5/5 |
| FCF Growth YoY | -81.6% | – |
| FCF/Sales | 0.8% | 4/5 |
| CapEx/Sales | 2.9% | 2/5 |
Operational Efficiency
| Metric | NUS | Rank |
|---|---|---|
| Asset Turnover | 1.23x | 4/5 |
| Receivables Turnover | 28.1x | 3/5 |
| Inventory Turnover | 2.2x | 6/7 |
| Fixed Assets Turnover | 3.6x | 5/5 |
| Days Sales Outstanding | 13 days | 3/5 |
| Days Inventory | 165 days | 2/7 |
| Payables Period | 32 days | 5/6 |
| Cash Conversion Cycle | 145 days | – |
Income Statement
| Metric | NUS | Rank |
|---|---|---|
| Total Revenue | $1.38B | 4/5 |
| Operating Income | -$10M | 7/7 |
| Net Income | -$218M | 8/8 |
| SG&A Expense | $881M | 5/6 |
| Cost of Goods Sold | $424M | 5/8 |
Dividend & Shareholder Information
| Metric | NUS | Rank |
|---|---|---|
| Dividends Per Share | $0.24 | – |
| Shares Outstanding | 49M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $508M | 45.3% of assets |
| Cash & Short-term Investments | $190M | 16.9% of assets |
| Accounts Receivable | $49M | 4.4% of assets |
| Inventory | $192M | 17.1% of assets |
| Total Liabilities | $579M | 51.6% of assets |
| Short-term Debt | $219M | 19.5% of assets |
NUS quarterly financials and insider trading
Nu Skin Enterprises, Inc. (NUS) industry peers
Companies classified under the same SEC industry code as Nu Skin Enterprises, Inc. (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere NUS sits on the market map
Nu Skin Enterprises, Inc. (NUS) stock news
Loading...
Nu Skin Enterprises, Inc. (NUS) stock forecast FAQ
What is the Nu Skin Enterprises, Inc. (NUS) stock forecast?
On Oct. 14, 2026, NUS is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Nu Skin Enterprises, Inc. stock predictions?
A per-ticker accuracy statistic for NUS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Nu Skin Enterprises, Inc. forecasts updated?
Nu Skin Enterprises, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Nu Skin Enterprises, Inc.'s industry peers?
8 issuers in our coverage, NUS included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cencora, Inc. (COR), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Hwh International Inc. (ESYN), Cosmos Health Inc. (COSM).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.